Patents by Inventor Bruce Neri
Bruce Neri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10436786Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: GrantFiled: January 12, 2016Date of Patent: October 8, 2019Assignee: Société Des Produits Nestlé S.A.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20160245814Abstract: Methods for identifying and evaluating biochemical entities useful as biomarkers for kidney cancer are described. Suites of small molecule entities as biomarkers for clear cell papillary kidney cancer are also described.Type: ApplicationFiled: September 26, 2014Publication date: August 25, 2016Inventors: Bruce NERI, Steven M. STIRDIVANT
-
Publication number: 20160123984Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: ApplicationFiled: January 12, 2016Publication date: May 5, 2016Applicant: NESTEC S.A.Inventors: SHARAT SINGH, JEANNE HARVEY, PHILLIP KIM, XINJUN LIU, LIMIN LIU, ROBERT BARHAM, BRUCE NERI
-
Patent number: 9274116Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: GrantFiled: November 26, 2013Date of Patent: March 1, 2016Assignee: NESTEC S.A.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20150065366Abstract: Methods for identifying and evaluating biochemical entities useful as biomarkers for bladder cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for bladder cancer.Type: ApplicationFiled: November 8, 2012Publication date: March 5, 2015Inventors: Jonathan E. McDunn, Regis Perichon, Bruce Neri, Bryan Wittmann
-
Publication number: 20140349865Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: ApplicationFiled: November 26, 2013Publication date: November 27, 2014Applicant: NESTEC S.A.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20140343865Abstract: Methods for identifying and evaluating biochemical entities useful as biomarkers for kidney cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for kidney cancer.Type: ApplicationFiled: December 7, 2012Publication date: November 20, 2014Inventors: Meredith V. Brown, Kay A. Lawton, Bruce Neri, Yang Chen
-
Publication number: 20140303228Abstract: The disclosure provides biomarkers of amyotrophic lateral sclerosis (ALS). The disclosure also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.Type: ApplicationFiled: October 17, 2012Publication date: October 9, 2014Inventors: Kay A. Lawton, Meredith V. Brown, Bruce Neri, Rebecca Caffrey, Michael V. Milburn
-
Patent number: 8609349Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: GrantFiled: April 4, 2012Date of Patent: December 17, 2013Assignee: Nestec S.A.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20130217647Abstract: Biomarkers (and suites of biomarkers) relating to prostate cancer are provided, as well as methods for using such biomarkers (ans suites thereof), including early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy.Type: ApplicationFiled: July 27, 2011Publication date: August 22, 2013Applicant: METABOLON, INC.Inventors: Jeffrey R. Shuster, Matthew W. Mitchell, Jonathan E. McDunn, Bruce Neri
-
Publication number: 20130045880Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: ApplicationFiled: April 4, 2012Publication date: February 21, 2013Applicant: Prometheus Laboratories Inc.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Patent number: 8315818Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.Type: GrantFiled: December 10, 2010Date of Patent: November 20, 2012Assignee: Nestec S.A.Inventors: Augusto Lois, Bruce Neri
-
Patent number: 8163499Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: GrantFiled: July 28, 2009Date of Patent: April 24, 2012Assignee: Prometheus Laboratories Inc.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20110244465Abstract: The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug.Type: ApplicationFiled: February 9, 2011Publication date: October 6, 2011Applicant: Prometheus Laboratories Inc.Inventors: Jeanne Harvey, Bruce Neri, Sharat Singh
-
Publication number: 20110218956Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.Type: ApplicationFiled: December 10, 2010Publication date: September 8, 2011Applicant: Prometheus Laboratories Inc.Inventors: Augusto Lois, Bruce Neri
-
Patent number: 7943328Abstract: The present invention provides methods, systems, and code for accurately classifying or diagnosing a sample from an individual as an IBS sample. The methods and systems of the present invention are useful for ruling out one or more diseases or disorders that share a similar clinical presentation as IBS followed by identifying (i.e., ruling in) IBS using statistical algorithm(s) and/or empirical data. In particular, the methods and systems of the present invention use a first combination of learning statistical classifier systems to rule out IBD with an accuracy of greater than about 90% and a second combination of learning statistical classifier systems to rule in IBS in a non-IBD sample with an accuracy of greater than about 80%.Type: GrantFiled: February 26, 2007Date of Patent: May 17, 2011Assignee: Prometheus Laboratories Inc.Inventors: Augusto Lois, Bruce Neri
-
Patent number: 7908091Abstract: The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug.Type: GrantFiled: March 16, 2007Date of Patent: March 15, 2011Assignee: Prometheus Laboratories Inc.Inventors: Jeanne Harvey, Bruce Neri, Sharat Singh
-
Patent number: 7873479Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.Type: GrantFiled: November 30, 2006Date of Patent: January 18, 2011Assignee: Prometheus Laboratories Inc.Inventors: Augusto Lois, Bruce Neri
-
Publication number: 20100167945Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.Type: ApplicationFiled: July 28, 2009Publication date: July 1, 2010Applicant: Prometheus Laboratories, Inc.Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
-
Publication number: 20100094560Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions.Type: ApplicationFiled: October 16, 2008Publication date: April 15, 2010Applicant: PROMETHEUS LABORATORIES INC.Inventors: AUGUSTO LOIS, BRUCE NERI